Twist Bioscience Corp Reports 16.9% Revenue Growth

By Chris Stiles • Tuesday, February 03 15:36 • Permanent Link

Twist Bioscience Corp has recently released its 10-Q report, revealing a 16.9% growth in revenues to $103.7 million from $88.7 million for the three months ended December 31, 2025, driven by an increase in NGS Applications and DNA Synthesis and Protein Solutions revenues. The company's core business involves manufacturing and selling synthetic DNA-based products used in various industries, including therapeutics, diagnostics, industry and applied, academic research and government, and global supply partners revenue.

The 10-Q report also highlights the financial performance of Twist Bioscience Corp. The company reported a net loss of $30.5 million for the three months ended December 31, 2025, compared to a net loss of $31.6 million for the same period in 2024. As of December 31, 2025, the company had accumulated a net deficit of $1,350.1 million and cash, cash equivalents, and short-term investments of $197.9 million.

The report further details the breakdown of revenues by geography, products, and industries. For the three months ended December 31, 2025, revenues from the Americas accounted for 56%, EMEA for 37%, and APAC for 7%. The company's revenues were primarily generated from DNA synthesis and protein solutions (49%) and NGS applications (51%). Additionally, the report provided insights into the number of genes shipped, which increased to approximately 271,000 genes for the three months ended December 31, 2025, compared to approximately 205,000 genes in the same period in 2024.

In terms of expenses, the report outlined a decrease in research and development expenses by 20% to $17.1 million and an increase in selling, general, and administrative expenses by 24% to $69.7 million for the three months ended December 31, 2025, compared to the same period in 2024. The company also reported a gross margin of 52.0% for the three months ended December 31, 2025, compared to 48.3% in the same period of the prior year.

As a result of these announcements, the company's shares have moved 0.34% on the market, and are now trading at a price of $41.41. For more information, read the company's full 10-Q submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.